<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02913196</url>
  </required_header>
  <id_info>
    <org_study_id>1509016578</org_study_id>
    <nct_id>NCT02913196</nct_id>
  </id_info>
  <brief_title>Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC</brief_title>
  <official_title>A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Weill Medical College of Cornell University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, Phase I study of apalutamide in combination with abiraterone acetate,&#xD;
      docetaxel and prednisone in patients with metastatic mastrate resistant prostate cancer&#xD;
      (mCRPC).&#xD;
&#xD;
      This study is designed to determine the dose that apalutamide can be administered safely in&#xD;
      combination with abiraterone acetate, docetaxel and prednisone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects are enrolled in up to three 3-6-subject cohorts and are administered combination&#xD;
      (apalutamide, abiraterone acetate and docetaxel plus prednisone) according to a&#xD;
      dose-escalation schedule. The first dose of docetaxel infusion begins on Day 1 Cycle 1. Daily&#xD;
      oral apalutamide, abiraterone acetate plus twice-daily oral prednisone begins on Day 1 Cycle&#xD;
      1. Docetaxel 1-hour infusions are administered intravenously every 3 weeks (Q3W), preceded by&#xD;
      oral dexamethasone. While a subject is receiving chemotherapy, a treatment cycle is defined&#xD;
      as 21 days. Dose limiting toxicity (DLT) determination is based on toxicities observed within&#xD;
      the initial 2 cycles defined as 6 weeks. DLT will be assessed before the start of the third&#xD;
      docetaxel infusion. Once a combination dose is determined to be safe (i.e. no more than 2 of&#xD;
      6 subjects experience DLT), the next cohort will enroll. Subjects remain at their allocated&#xD;
      combination dose until the maximum tolerated dose (MTD) is determined.&#xD;
&#xD;
      The primary objective is to determine a safe dose combination of apalutamide plus abiraterone&#xD;
      acetate, docetaxel, prednisone in subjects with mCRPC.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 30, 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Actual">June 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLT)</measure>
    <time_frame>From the time of study drug administration till PSA progression or study completion (~36 months)</time_frame>
    <description>Dose limiting toxicities will be measured by using the Common Terminology Criteria for Adverse Events or CTCAE version 4.0 which uses a grading scale from 1-5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the number of subjects with prostate-specific antigen (PSA) response</measure>
    <time_frame>Starting after 12 weeks, at the beginning of Week 4 of combination therapy with docetaxel, apalutamide, abiraterone acetate plus prednisone until PSA progression or study completion (~36 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PSA response</measure>
    <time_frame>At the start of treatment until PSA progression or study completion (~36 months)</time_frame>
    <description>PSA response will be captured through blood sample collection and radiographic scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the time to PSA progression</measure>
    <time_frame>At the start of treatment until PSA progression or study completion (~36 months)</time_frame>
    <description>PSA progression will be determined by protocol-specific/modified Prostate Cancer Clinical Trials Working Group 3 (PCWG3) criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change is radiographic progression-free survival</measure>
    <time_frame>Images will be collected at baseline, 12 weeks and at end of study, an average of 100 months</time_frame>
    <description>Radiographic progression will be determined via scans metric of CT, MRI and Bone scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CellSearch circulating tumor cells (CTC) enumration</measure>
    <time_frame>Collected at baseline, 12 weeks and at end of study, an average of 100 months</time_frame>
    <description>CTCs will be collected via blood sample collection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Prostate Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apalutamide, 120 mg (cohort 1), 240 mg (cohort 2), 180 mg (cohort 3) Abiraterone Acetate 1000mg Prednisone 10mg Docetaxel 75 mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.&#xD;
Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>ARN-509</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone acetate</intervention_name>
    <description>Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.&#xD;
Dose: 1000 mg QD</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.&#xD;
Dose: 75 mg/m2 Q3W</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>Taxotere</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Dose: 5 mg BID</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>Deltasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Histologically or cytologically confirmed adenocarcinoma of prostate&#xD;
&#xD;
          2. Documented progressive metastatic CRPC based on at least one of the following&#xD;
             criteria:&#xD;
&#xD;
               1. PSA progression according to Prostate Cancer Working Group 3 (PCWG3) criteria&#xD;
&#xD;
               2. Objective radiographic progression in soft tissue, according to modified Response&#xD;
                  Evaluation Criteria In Solid Tumors (RECIST) or bone scans&#xD;
&#xD;
          3. ECOG performance status of 0-2&#xD;
&#xD;
          4. Have serum testosterone &lt; 50 ng/dL. Subjects must continue primary androgen&#xD;
             deprivation with an LHRH/GnRH analogue (agonist/antagonist) if they have not undergone&#xD;
             orchiectomy&#xD;
&#xD;
          5. Age &gt;18 years&#xD;
&#xD;
          6. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               1. Absolute neutrophil count &gt;1,500/cells/mm3&#xD;
&#xD;
               2. Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
               3. Platelet count &gt;100,000 x 109/microliter&#xD;
&#xD;
               4. Serum creatinine &lt;1.5 x upper limit of normal (ULN) or calculated creatinine&#xD;
                  clearance ≥ 60 mL/min/1.73 m2 by Cockcroft-Gault&#xD;
&#xD;
               5. Serum albumin ≥3.2 g/dL&#xD;
&#xD;
               6. Serum potassium ≥3.5 mmol/L&#xD;
&#xD;
          7. Patients must be able to take oral medication without crushing, dissolving or chewing&#xD;
             tablets&#xD;
&#xD;
          8. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
          9. Medications known to lower the seizure threshold (see list under prohibited&#xD;
             medications) must be discontinued or substituted at least 4 weeks prior to study drug&#xD;
             initiation&#xD;
&#xD;
         10. Patients on stable dose of bisphosphonates or RANK-L inhibitor, Denosumab, which have&#xD;
             been started no less than 4 weeks prior to treatment start, may continue on this&#xD;
             medication&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Liver Function&#xD;
&#xD;
               1. If total bilirubin is &gt;1.5 x ULN (NOTE: in subjects with Gilbert's syndrome, if&#xD;
                  total bilirubin is &gt;1.5 x ULN, measure direct and indirect bilirubin and if&#xD;
                  direct bilirubin is within normal range, subject may be eligible) or&#xD;
&#xD;
               2. Alanine (ALT) or aspartate (AST) aminotransferase &gt;1.5xULN (or &gt;5xULN for subject&#xD;
                  with liver metastasis) concomitant with alkaline phosphatase &gt;2.5xULN (or &gt;5xULN&#xD;
                  for subjects with bone or liver metastases) or&#xD;
&#xD;
               3. Alanine (ALT or aspartate (AST) aminotransferase &gt;2.5xULN (or &gt;5xULN for subjects&#xD;
                  with liver metastasis&#xD;
&#xD;
          2. Use of investigational drugs (including vaccines) or implantation of invasive medical&#xD;
             device ≤4 weeks or &lt;5 half-lives of Cycle 1, Day 1 or current enrollment in&#xD;
             investigational drug or device study&#xD;
&#xD;
          3. Prior exposure to apalutamide. Prior exposure to abiraterone acetate and/or other&#xD;
             CYP17 inhibitors, enzalutamide is allowed (but not preferred) only during the dose&#xD;
             escalation period&#xD;
&#xD;
          4. Prior chemotherapy for advanced prostate cancer. Prior chemotherapy for any other&#xD;
             disease within 3 years&#xD;
&#xD;
          5. Prior systemic beta-emitting bone-seeking radioisotopes (i.e. strontium-90)&#xD;
&#xD;
          6. Pre-existing neuropathy ≥Grade 2&#xD;
&#xD;
          7. Systemic azole treatment (e.g. Fluconazole, itracanozole) ≤2 weeks of Cycle 1 Day 1&#xD;
&#xD;
          8. Use of potent inducers or inhibitors of CYP3A4 activity ≤2 weeks prior to Day 1 Cycle&#xD;
             1&#xD;
&#xD;
          9. History of adrenal insufficiency or hyperaldosteronism&#xD;
&#xD;
         10. Active or symptomatic viral hepatitis&#xD;
&#xD;
         11. Chronic liver disease&#xD;
&#xD;
         12. Brain metastases or leptomeningeal disease&#xD;
&#xD;
         13. Known allergies, hypersensitivity or intolerance to abiraterone acetate, apalutamide,&#xD;
             docetaxel, dexamethasone, prednisone, or their excipients&#xD;
&#xD;
         14. Use of herbal, alternative and food supplements (i.e. PC-Spes, Saw Palmetto, St John&#xD;
             Wort, etc) must be discontinued before treatment start. Daily Multi-vitamin, calcium&#xD;
             and Vitamin D is allowed&#xD;
&#xD;
         15. Surgery or local prostatic intervention within 30 days of first dose. [Note: Any&#xD;
             clinically relevant sequelae from surgery must have resolved prior to Day 1 Cycle 1]&#xD;
&#xD;
         16. Radiation therapy for treatment of prostate cancer ≤4 weeks of Day 1 Cycle 1&#xD;
&#xD;
         17. Current evidence of any of the following:&#xD;
&#xD;
               1. Uncontrolled hypertension (defined as blood pressure of &gt;150 mmHg systolic and/or&#xD;
                  &gt;100 mmHg diastolic on medication)&#xD;
&#xD;
               2. Gastrointestinal disorder affecting absorption&#xD;
&#xD;
               3. Active infection (e.g., human immunodeficiency virus [HIV] or viral hepatitis) or&#xD;
                  other medical condition that would make prednisone/prednisolone (corticosteroid)&#xD;
                  use contraindicated&#xD;
&#xD;
               4. Any chronic medical condition requiring a higher dose of corticosteroid than 10&#xD;
                  mg prednisone/prednisolone once daily&#xD;
&#xD;
               5. Any condition that in the opinion of the investigator, would preclude&#xD;
                  participation in this study&#xD;
&#xD;
               6. Patients with baseline severe hepatic impairment (Child Pugh Class C)&#xD;
&#xD;
         18. Severe or unstable angina, myocardial infarction, symptomatic congestive heart&#xD;
             failure, arterial or venous thromboembolic events (e.g., pulmonary embolism,&#xD;
             cerebrovascular accident including transient ischemic attacks), or clinically&#xD;
             significant ventricular arrhythmias within 6 months prior to treatment start or New&#xD;
             York Heart Association (NYHA) Class II to IV heart disease&#xD;
&#xD;
         19. Seizure or known condition that may pre-dispose to seizure (including but not limited&#xD;
             to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior&#xD;
             to randomization, brain arteriovenous malformation; or intracranial masses such as&#xD;
             schwannomas and meningiomas that are causing edema or mass effect)&#xD;
&#xD;
         20. Having partners of childbearing potential and not willing to use a method of birth&#xD;
             control deemed acceptable by the principle investigator and chairperson during the&#xD;
             study and for 1 week after last study drug administration&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana Molina, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GU Research Network/Urology Cancer Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 16, 2016</study_first_submitted>
  <study_first_submitted_qc>September 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2016</study_first_posted>
  <last_update_submitted>August 26, 2021</last_update_submitted>
  <last_update_submitted_qc>August 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

